Company and Document Details
AGM Details
The 29th Annual General Meeting will be held on Wednesday, September 23, 2026 at 04:00 PM (IST) through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The Registered Office of the Company shall be deemed to be the venue of the AGM.
Voting Arrangements
In compliance with Section 108 of the Companies Act 2013 and Regulation 44 of SEBI (LODR) Regulations, 2015, the Company is providing remote e-voting facility through Central Depository Services (India) Limited (CDSL).
Key Voting Dates:
- Cut-off date for eligibility: Wednesday, September 16, 2026
- Remote e-voting period: September 20, 2026 (09:00 AM IST) to September 22, 2026 (05:00 PM IST)
- Scrutinizer: Mr. P. Eswaramoorthy of M/s. P. Eswaramoorthy & Co, Company Secretaries
Business to be Transacted
Ordinary Business:
1. To receive, consider and adopt the Audited Financial Statements for FY ended March 31, 2026 with Reports of Board of Directors and Auditors
2. To appoint director in place of Dr. Kavetha Sundaramoorthy (DIN 02050806) who retires by rotation
Special Business:
Item 3: Approval of revision in remuneration of Ms. Sangeetha Sundaramoorthy (DIN 01859252), Managing Director
- Current remuneration: ₹3,50,000 per month
- Proposed revised remuneration: ₹6,00,000 per month
- Effective date: August 10, 2026
- Tenure: Remaining period ending August 14, 2028
- Breakdown of revised monthly remuneration:
- Basic: ₹2,40,000
- Dearness Allowance: ₹2,40,000
- House Rent Allowance: ₹60,000
- Medical Allowance: ₹30,000
- Transport Allowance: ₹30,000
- Provident Fund, Gratuity: As per the limits
- In case of inadequate profits, the above remuneration shall be paid as minimum remuneration
- Board authorized to alter/vary terms within statutory limits
Item 4: Approval for continuation of payment of remuneration to Dr. Kuttapalayam Songappan Ramalingam (DIN 01016571), Non-Executive Non-Independent Director
- Remuneration: ₹1,00,000 per month for FY 2026-27
- Requires special resolution pursuant to Regulation 17(6)(ca) of SEBI (LODR) Regulations, 2015
Financial Performance Context (for Item 3)
The explanatory statement provides FY 2025-26 financial data:
- Turnover: ₹5,489.03 lakh
- Profit After Tax: ₹8.04 lakh
- Net Worth: ₹60.14 lakh
- Earnings Per Share: ₹0.04
- Reasons for inadequate profits: Investments in skilled manpower resulting in higher depreciation & increased operating cost
- Expected improvement: New centres expected to benefit long-term through higher margin; cost control measures underway
Director Background Information
Ms. Sangeetha Sundaramoorthy (Managing Director)
- Software Professional associated with company since 2006
- Appointed Whole-Time Director in 2009
- Past remuneration: ₹3,50,000 per month
- Recognition: "Budding Entrepreneur – Healthcare" award by The Times of India in 2021
- Shareholding: 72,74,272 shares (34.98%)
- Related to Dr. Kavetha Sundaramoorthy (sister)
Dr. Kuttapalayam Songappan Ramalingam (Non-Executive Director)
- Over 43 years experience in Clinical Nephrology
- Promoter of Coimbatore Kidney Centre and Specialty Hospitals
- Remuneration last drawn: ₹12,00,000 per annum (₹1,00,000 per month)
- Shareholding: 3,02,894 shares (1.46%)
Dr. Kavetha Sundaramoorthy (Director retiring by rotation)
- Board-certified Psychiatrist with specialization in Adult and Child/Adolescent Psychiatry
- Over 15 years of clinical experience
- Harvard University alumnus with Farley Award recognition
- Shareholding: 5,70,993 shares (2.75%)
- Related to Ms. Sangeetha Sundaramoorthy (sister)
Additional AGM Information
- Annual Report available on company website: https://www.lotuseye.org/Investor/Annual-Report/Annual-Report-for-2025-2026.pdf
- Physical copies available on request to companysecretary@lotuseye.org
- Members must register/update mobile/email with RTA MUFG Intime India Private Limited
- Unclaimed dividends for 7+ years liable for transfer to Investor Education and Protection Fund (IEPF)
- Results of voting will be placed on company website and communicated to stock exchanges